Reduction in requirements for allogeneic blood products: Pharmacologic methods

Annals of Thoracic Surgery

Volumn 62, Issue 6, 1996, Pages 1944-1950

  Janssens, Marc ^a,b   Hartstein, Gary ^a   David, Jean Louis ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; PROSTACYCLIN; TRANEXAMIC ACID;

BLEEDING; BLOOD; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; HEART SURGERY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0030550728     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00940-X     Document Type: Article

References (61)

1. 1. Radegran K, Aren C, Teger-Nilsson AC. Prostacyclin infusion during extracorporeal circulation for coronary bypass. J Thorac Cardiovasc Surg 1982;83:205-11.
2. 2. Fish KJ, Sarnquist FH, Van Steennis C, et al. A prospective randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operation. J Thorac Cardiovasc Surg 1986;91:436-42.
3. 3. Malpass TW, Amory DW, Harker LA, Ivey TD, Williams DB. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1984;87:550-5.
4. 4. Carteaux JP, Roux S, Kuhn H, Tschopp T, Colombo V, Hadvary P. Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106:834-41.
5. 5. Mannucci PM. Desmopressin (DDAVP) for treatment disorders of hemostasis. Prog Hemost Thromb 1986;8:19-45.
6. 6. Sloand EM, Alyono D, Klein HG, et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994;46:199-207.
7. 7. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993;7:425-30.
8. 8. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84:2063-70.
9. 9. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986;314:1402-6.
10. 10. Czer LSC, Bateman TM, Gray RJ, et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987;9:1139-47.
11. 11. Rocha E, Hidalgo F, LLorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921-7.
12. 12. Cattaneo M, Mannucci PM. Desmopressin and blood loss after cardiac surgery. Lancet 1993;342:812.
13. 13. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991;74:988-96.
14. 14. Gratz I, Koehler J, Olsen D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992;104:1417-22.
15. 15. Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33-6.
16. 16. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992;77:38-46.
17. 17. Vander Salm TJ, Ansell JE, Okike ON, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988;95:538-40.
18. 18. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99-108.
19. 19. DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989;96:27-30.
20. 20. Arom KV, Emery RW. Decreased postoperative drainage with addition of ∈-aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg 1994;57:1108-13.
21. 21. Horrow JC, Hlavacek J, Strong D, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990;99:70-4.
22. 22. Karski JM, Teasdale SJ, Norman PH, Carroll JA, Weisel RD, Glynn MF. Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth 1993;7:431-5.
23. 23. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:383-92.
24. 24. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
25. 25. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083-91.
26. 26. Emerson TE. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 1989;7: 127-40.
27. 27. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
28. 28. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
29. 29. Van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
30. 30. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery. Lancet 1988; 1:366-7.
31. 31. Dietrich W, Barankay A, Hähnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992;6:324-7.
32. 32. Havel M, Teufelsbauer H, Knöbl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.
33. 33. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-661.
34. 34. Tabuchi N, Van Oeveren W, Eijsman L, Roozendaal KJ, Gu YJ, Wildevuur CRH. Preserved hemostasis during the combined use of aprotinin and aspirin in CABG operations. In: Freidel N, Hetzer R, Royston D, eds. Blood use in cardiac surgery. New York: Springer-Verlag, 1991:245-51.
35. 35. Schönberger JPAM, Bredee JJ, van Oeveren W, et al. Preoperative therapy of low-dose aspirin in internal mammary artery bypass operations with and without low-dose aprotinin. J Thorac Cardiovasc Surg 1993;106:262-7.
36. 36. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991;5:467-74.
37. 37. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989;3:181-8.
38. 38. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993;106:11-8.
39. 39. Tabuchi N, De Haan J, Boonstra PW, Huet RCG, van Oeveren W. Aprotinin effect on platelet function and clotting during cardiopulmonary bypass. Eur J Cardiothorac Surg 1994;8:87-90.
40. 40. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
41. 41. Royston BD, Royston D, Pearson JD. Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolysis 1992;3:737-42.
42. 42. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass - effects on the Hageman factor (FXII)-kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992;3:99-104.
43. 43. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6: 76-100.
44. 44. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-10.
45. 45. Böhrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 1990;4:222-5.
46. 46. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
47. 47. Umbrain V, Christiaens F, Camu F. Intraoperative coronary thrombosis: can aprotinin and protamin be incriminated? J Cardiothorac Vasc Anesth 1994;8:198-201.
48. 48. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-53.
49. 49. Havel M, Grabenwöger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
50. 50. Royston D. Aprotinin in open heart surgery: background and results in patients having aortocoronary bypass grafts. Perfusion 1990;5:63-72.
51. 51. Van Oeveren W, van Oeyeren B, Wildevuur CRH. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104:210-1.
52. 52. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83:679-89.
53. 53. Lemmer JHJ, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-bind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-53.
54. 54. Blauhut B, Gross C, Necek S, Doran JE, Späth P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
55. 55. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995;59:132-6.
56. 56. Feindt PR, Walcher S, Volkmer I, et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995;60:1076-80.
57. 57. Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-24.
58. 58. Goldstein DJ, DeRosa CM, Mongero LB, et al. Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995;110: 1615-22.
59. 59. Wüthrich B, Schmid P, Schmid ER, Tornic M, Johansson SG. IgE-mediated anaphylactic reaction to aprotinin during anaesthesia. Lancet 1992;340:173-4.
60. 60. Dietrich W, Späth P, Ebell A, Richter JA, Incidence of anaphylactic reactions to aprotinin - analysis of 248 reexposures to aprotinin. Anesthesiology 1995;83:A104.
61. 61. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993;88(Suppl 2):432-6.